Instrument Inactif

Communiqués Delcath Systems, Inc. Nasdaq

Actions

US24661P1049

Equipement, fournitures et distribution médicale

Cours en clôture Nasdaq
- ^USD	-

06/08	Delcath Systems, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
06/08	Transcript : Delcath Systems, Inc., Q2 2026 Earnings Call, Aug 06, 2026

Communiqués

31/08	Delcath Systems to Participate in Upcoming Investor Conferences	BU
06/08	Delcath Systems Reports Second Quarter 2026 Results and Business Highlights	BU
28/07	Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference	BU
27/07	Delcath Systems to Host Second Quarter 2026 Earnings Call	AQ
23/07	Delcath Systems to Host Second Quarter 2026 Earnings Call	BU
16/07	Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
10/07	Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO in Liver-Dominant Metastatic Breast Cancer	AQ
09/07	Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer	BU
26/05	Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts	BU
15/05	Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
12/05	Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference	BU
07/05	Delcath Systems Reports First Quarter 2026 Results and Business Highlights	BU
07/05	Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026	BU
23/04	Delcath Systems to Host First Quarter 2026 Earnings Call	BU
06/04	Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma	BU
01/04	Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting	BU
03/03	Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology	BU
26/02	Delcath Systems Reports Fourth Quarter and Full Year 2025 Results	BU
12/02	Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call	BU
27/01	Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference	BU
21/01	Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
09/01	Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results	BU
31/12	Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma	BU
03/12	Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma	BU
20/11	Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program	BU